A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients

Journal of Clinical Psychiatry

Volumn 64, Issue 8, 2003, Pages 921-926

  Hong, Chen Jee ^a,b   Hu, Wei Herng ^c   Chen, Chwen Cheng ^d   Hsiao, Cheng Cheng ^e   Tsai, Shih Jen ^a,b   Ruwe, Frank J L ^f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI CITY PSYCHIATRIC CENTER   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^e CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^f NV ORGANON   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; MIRTAZAPINE;

ADULT; AGED; ANOREXIA; ARTICLE; CHINESE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA MULTIFORME; FEMALE; FLU LIKE SYNDROME; HAMILTON SCALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; VERTIGO; WEIGHT GAIN;

EID: 0042512501     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v64n0810     Document Type: Article

References (18)

1. de Boer T. The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission. Int Clin Psychopharmacol 1995;10(suppl 4): 19-23
2. Smith WT, Glaudin V, Panagides J, et al. Mirtazapine vs amitriptyline vs placebo in the treatment of major depressive disorder. Psychopharmacol Bull 1990;26:191-196
3. Bremner JD. A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression. J Clin Psychiatry 1995;56:519-525
4. Claghorn JL, Lesem MD. A double-blind placebo-controlled study of Org 3770 in depressed outpatients. J Affect Disord 1995;34:165-171
5. Wheatley DP, van Moffaert M, Timmerman L, et al. and the Mirtazapine-Fluoxetine Study Group. Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. J Clin Psychiatry 1998;59:306-312
6. Leinonen E, Skarstein J, Behnke K, et al. Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group. Int Clin Psychopharmacol 1999;14:329-337
7. Benkert O, Szegedi A, Kohnen R. Mirtazapine compared with paroxetine in major depression. J Clin Psychiatry 2000;61:656-663
8. Sramek JJ, Pi EH. Ethnicity and antidepressant response. Mt Sinai J Med 1996;63:320-325
9. Jann MW, Cohen LJ. The influence of ethnicity and antidepressant pharmacogenetics in the treatment of depression. Drug Metabol Drug Interact 2000;16:39-67
10. Hamilton M. A rating scale for depression. J of Neurol Neurosurg Psychiatry 1960;23:56-62
11. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology. US Dept Health, Education, and Welfare publication (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976:218-222
12. World Health Orgainization. Adverse Reactions Terminology (WHO-ART). Geneva, Switzerland: World Health Orgainization; 1994
13. Holm KJ, Markham A. Mirtazapine: a review of its use in major depression. Drugs 1999;57:607-631
14. Lin KM, Poland RE, Wan YJ, et al. The evolving science of pharmacogenetics: clinical and ethnic perspectives. Psychopharmacol Bull 1996; 32:205-217
15. Kasper S. Efficacy of antidepressants in the treatment of severe depression: the place of mirtazapine. J Clin Psychopharmacol 1997; 17(suppl 1):19S-28S
16. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. CNS Drugs 1995; 4(suppl 1):39-48
17. Montgomery SA. Safety of mirtazapine: a review. Int Clin Psychopharmacol 1995;10(suppl 4):37-45
18. Hirschfeld RMA, Russell JM, Delgado PL, et al. Predictors of response to acute treatment of chronic and double depression with sertraline or imipramine. J Clin Psychiatry 1998;59:669-675